- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | RenovoRx: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| Do | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Do | RenovoRx GAAP EPS of -$0.08 beats by $0.01, revenue of $0.04M misses by $0.21M | 3 | Seeking Alpha | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 06.08. | RenovoRx expands commercial footprint to 13 cancer centers | 1 | Investing.com | ||
| 06.08. | RenovoRx, Inc.: RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire | 56 | GlobeNewswire (Europe) | RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are... ► Artikel lesen | |
| 28.07. | RenovoRx startet Post-Marketing-Studie für Krebstherapie-System | - | Investing.com Deutsch | ||
| 28.07. | RenovoRx to launch post-marketing registry study for cancer device | 1 | Investing.com | ||
| 27.06. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 25.06. | RenovoRx-Aktionäre wählen Direktoren und genehmigen Änderungen am Anreizplan | 2 | Investing.com Deutsch | ||
| 25.06. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Ascendiant Capital raises RenovoRx stock price target to $11.50 | 1 | Investing.com | ||
| 15.05. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.04. | H.C. Wainwright maintains Buy rating on RenovoRx stock | 2 | Investing.com | ||
| 01.04. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | RenovoRx erwartet Wachstum durch Neuaufträge und klinische Studie | 1 | Investing.com Deutsch | ||
| 01.04. | RenovoRx projects growth with new orders and clinical trial | 1 | Investing.com | ||
| 31.03. | RenovoRx, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 14.11.24 | RenovoRx, Inc.: RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights | 148 | GlobeNewswire (Europe) | Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in... ► Artikel lesen | |
| 25.09.24 | RenovoRx, Inc.: RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians | 277 | GlobeNewswire (Europe) | LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a local... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,338 | -2,64 % | Ihre wichtigsten Termine: Porsche, Thyssenkrupp Nucera, Eon, Evotec, Brenntag, Sixt & Tui legen Zahlen vor | © Foto: PorscheGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45 Uhr, Deutschland:... ► Artikel lesen | |
| QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,15 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| BIONTECH | 96,55 | -0,21 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
| VALNEVA | 4,814 | +9,66 % | Rheinmetall: Schwach, aber... - Bayer, Commerzbank, Deutz, ThyssenKrupp und Valneva im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BOLT PROJECTS | 10,700 | +27,53 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| ARCELLX | 72,03 | +0,24 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 14,765 | +1,97 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| AVIDITY BIOSCIENCES | 46,360 | +0,59 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| IMMUNOVANT | 15,150 | -0,33 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 | Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025All other... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 20,840 | -0,33 % | Sionna Therapeutics Non-GAAP EPS of -$0.41 | ||
| NUVALENT | 75,68 | -1,51 % | Nuvalent to present pivotal lung cancer drug data at WCLC 2025 | ||
| EDGEWISE THERAPEUTICS | 14,040 | +0,79 % | Edgewise Therapeutics stock price target raised to $49 at RBC Capital | ||
| COGNITION THERAPEUTICS | 1,730 | +4,22 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease | - Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:... ► Artikel lesen | |
| QUANTUM-SI | 1,130 | +2,26 % | Quantum-Si's Q2 Loss In Line With Estimates, Revenues Rise Y/Y |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,245 (-19,85 %) liegt der Kurs bei 0,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.